Statement of Changes in Beneficial Ownership (4)
10 February 2021 - 8:26AM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Seymour Albert |
2. Issuer Name and Ticker or Trading Symbol
Homology Medicines, Inc.
[
FIXX
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Chief Scientific Officer |
(Last)
(First)
(Middle)
C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK |
3. Date of Earliest Transaction
(MM/DD/YYYY)
2/5/2021 |
(Street)
BEDFORD, MA 01730
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Employee Stock Option (Right to Buy) | $13.78 | 2/5/2021 | | A | | 78000 | | (1) | 2/5/2031 | Common Stock | 78000 | $0.00 | 78000 | D | |
Restricted Stock Units | (2) | 2/5/2021 | | A | | 13000 | | (3) | (3) | Common Stock | 13000 | $0.00 | 13000 | D | |
Explanation of Responses: |
(1) | The option vests in 48 equal monthly installments on the first day of each calendar month following January 1, 2021. |
(2) | Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. |
(3) | The restricted stock units will vest and settle as to one third of the restricted stock units on each of the first three anniversaries of January 1, 2021 so that such RSUs will become fully vested on January 1, 2024. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Seymour Albert C/O HOMOLOGY MEDICINES, INC. ONE PATRIOTS PARK BEDFORD, MA 01730 |
|
| Chief Scientific Officer |
|
Signatures
|
/s/ Bradford Smith, Attorney-in-Fact for Albert Seymour | | 2/9/2021 |
**Signature of Reporting Person | Date |
Homology Medicines (NASDAQ:FIXX)
Historical Stock Chart
From Apr 2024 to May 2024
Homology Medicines (NASDAQ:FIXX)
Historical Stock Chart
From May 2023 to May 2024